Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

MDGL - Madrigal Pharmaceuticals, Inc.... | Finranks

Home

MDGL

M

Madrigal Pharmaceuticals, Inc. (MDGL)

NMS – Real vaqt narxi. Valyuta: USD

510.68

-8.08 (-1.56%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

513.00

+2.32 (0.45%)

Bozordan keyin: Mar 27, 2026, 7:41 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?

Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now

Summit Therapeutics shares could drop later this year if it doesn't earn approval for its leading candidate. Madrigal Pharmaceuticals and Axsome Therapeutics could move in the opposite direction.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 15, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

2 Under-the-Radar Stocks to Buy and Hold

2 Under-the-Radar Stocks to Buy and Hold

Axsome Therapeutics has an exciting late-stage pipeline. Madrigal Pharmaceuticals is looking to dominate a large market with significant unmet needs.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M.

Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down

Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down

MDGL swings to a wider Q4 loss as expenses surge, but Rezdiffra sales top estimates and fuel revenue growth. The stock slides 11% in response to the mixed nature of the results.

Videolar

Madrigal Pharmaceuticals CEO: We're positioned for decades of growth

Press-relizlar

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 15, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M.

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

Fourth -quarter and full-year 2025 Rezdiffra ® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025 , more than 36,250 patients on Rezdiffra Built industry-leading MASH pipeline with more than 10 programs at multiple stages of development Reports cash, cash equivalents, restricted cash and marketable securities of $988.6 million as of Dec. 31, 2025 Company to host conference call today, Feb. 19, 2026, at 8 a.m. EST CONSHOHOCKEN, Pa.